Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals closes $270 million Alkeus acquisition, adding ALK-001 candidate

Neutral Impact 4 of 5 m&a Written later

Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, paying $270 million in cash and issuing 2,908,692 shares at closing. Alkeus shareholders may also receive up to $350 million in milestone payments tied to regulatory approval and first U.S. sales, plus revenue-sharing payments on future gildeuretinol sales. The filing does not provide financial results for Alkeus, so its effect on Tarsus's financials is not yet quantified.

Key points

  • Acquisition closed September 4, 2026, with Alkeus becoming a wholly-owned subsidiary of Tarsus
  • Up-front consideration: $270,000,000 in cash, subject to adjustments, plus 2,908,692 shares of common stock
  • Milestones up to $350 million: $250 million on U.S. regulatory approval of an Alkeus product, and $100 million in cash on first U.S. sale
  • Financial statements and pro forma information will be filed by amendment within 71 calendar days

The filing

CompanyTarsus Pharmaceuticals, Inc. (TARS)
Form8-K, current report
Filed with the SECSep 10, 2026, 4:05 PM ET
Accession number0001819790-26-000066

Items reported: 2.01 Acquisition or Disposition Completed8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.